AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31096012 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐E (‐50/+50 cmH2O) plus endotracheal suctioning
Number of subjects: 16
Study 31096012 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐E (‐30/+30 cmH2O) plus endotracheal suctioning
Number of subjects: 16
Study 31096012 — intervention group
Group type: COMPARATOR
Intervention: Isolated endotracheal suctioning (IES)
Number of subjects: 16
Study 30046018 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated phone heat warning system
Number of subjects: 1328
Study 30046018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warning)
Number of subjects: 1328
Study 26963592 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 24
Study 26963592 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (ND)
Number of subjects: 24
Study 25283470 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (serotonin-norepinephrine reuptake inhibitor)
Number of subjects: 92
Study 25283470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 23392399 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP (high-sensitivity C-reactive protein)
Number of subjects: 1441
Study 23392399 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAM-1 (intercellular adhesion molecule 1)
Number of subjects: 1441
Study 23392399 — intervention group
Group type: COMPARATOR
Intervention: VCAM-1 (vascular cell adhesion molecule 1)
Number of subjects: 1441
Study 23392399 — intervention group
Group type: COMPARATOR
Intervention: TNF-α receptor 1 (tumor necrosis factor α receptor 1)
Number of subjects: 1441
Study 20927577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) group
Number of subjects: 37
Study 20927577 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 18171181 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand gel
Number of subjects: 0
Study 18171181 — intervention group
Group type: COMPARATOR
Intervention: Control (no hand gel)
Number of subjects: 0
Study 17139600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with inhaled iloprost and bosentan
Number of subjects: 0
Study 17139600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with inhaled iloprost and sildenafil
Number of subjects: 0
Study 17139600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with bosentan and sildenafil
Number of subjects: 0
Study 17139600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with two or three of the mentioned drugs
Number of subjects: 0
Study 17139600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 12607159 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 208
Study 12607159 — intervention group
Group type: COMPARATOR
Intervention: Routine surgery
Number of subjects: 208
Study 11070991 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of somatostatin analogues
Number of subjects: 0
Study 11070991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists (e.g., bromocriptine)
Number of subjects: 0
Study 11070991 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma knife radiosurgery
Number of subjects: 0
Study 11070991 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 8865083 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-eccentric exercise clamp (PEC)
Number of subjects: 7
Study 8865083 — intervention group
Group type: COMPARATOR
Intervention: Control clamp (CC)
Number of subjects: 7
Study 1641148 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy test meal
Number of subjects: 11
Study 1641148 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein test meal
Number of subjects: 11
Study 1641148 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test meals
Number of subjects: 11
Study 6861871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine tablets (20-40 mg every 4 to 6 hours)
Number of subjects: 7
Study 6861871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine solution (20-40 mg every 4 to 6 hours)
Number of subjects: 7
Study 31497864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 732
Study 31497864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study 30501629 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic physical therapy focused on strengthening
Number of subjects: 0
Study 30501629 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic physical therapy containing placebo
Number of subjects: 0
Study 30501629 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized home exercise programs
Number of subjects: 0
Study 30501629 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study 26770048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (group D)
Number of subjects: 60
Study 26770048 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 60
Study 25264782 — intervention group
Group type: EXPERIMENTAL
Intervention: Biojector IM injection of rAd5 vaccine at 10^10 PU
Number of subjects: 31
Study 25264782 — intervention group
Group type: COMPARATOR
Intervention: Needle injection of rAd5 vaccine at 10^10 PU
Number of subjects: 31
Study 25264782 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of rAd5 vaccine
Number of subjects: 31
Study 25264782 — intervention group
Group type: COMPARATOR
Intervention: Biojector delivery of rAd5 vaccine
Number of subjects: 31
Study 22419732 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg plus pioglitazone (any dose)
Number of subjects: 1554
Study 22419732 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg plus pioglitazone (any dose)
Number of subjects: 1554
Study 22419732 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone alone (Pio alone)
Number of subjects: 1554
Study 20595675 — intervention group
Group type: EXPERIMENTAL
Intervention: Causative Classification System (CCS)
Number of subjects: 381
Study 20595675 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCO grade 1
Number of subjects: 381
Study 20595675 — intervention group
Group type: COMPARATOR
Intervention: TOAST
Number of subjects: 381
Study 17331805 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 51
Study 17331805 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 51
Study 16359548 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg/wk
Number of subjects: 793
Study 16359548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study 12445410 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 20
Study 12445410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9872708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 106
Study 9872708 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 106
Study 9872708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 9872708 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of both short-term and maintenance phases
Number of subjects: 106
Study 7608860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated participants
Number of subjects: 0
Study 7608860 — intervention group
Group type: COMPARATOR
Intervention: Sober participants
Number of subjects: 0
Study 2392794 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcricoid injection of 100 mg lignocaine
Number of subjects: 62
Study 2392794 — intervention group
Group type: COMPARATOR
Intervention: Spray as you go technique with 240 mg lignocaine
Number of subjects: 62
Study 373777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 45 mg/d
Number of subjects: 30
Study 373777 — intervention group
Group type: COMPARATOR
Intervention: Bromhexine 36 mg/d
Number of subjects: 30
Study 31915906 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HIIT (4×4 min bouts at 85-95% HR peak, 3×/week)
Number of subjects: 70
Study 31915906 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (30 min at 60-70% HR peak, 5×/week)
Number of subjects: 70
Study 31915906 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-HIIT (1×4 min bout at 85-95% HR peak, 3×/week)
Number of subjects: 70
Study 31915906 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction genotypes (H1, H2, H3, H4)
Number of subjects: 70
Study 31416746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 72
Study 31416746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 27726423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional steroids (8 mg of dexamethasone plus 2 mL of lidocaine)
Number of subjects: 0
Study 27726423 — intervention group
Group type: COMPARATOR
Intervention: Platelet-Rich Plasma (3 mL of PRP activated with 0.45 mL of 10% calcium gluconate)
Number of subjects: 0
Study 26375468 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 1030
Study 26375468 — intervention group
Group type: COMPARATOR
Intervention: Control (questionnaire only)
Number of subjects: 1030
Study 23620431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics near infrared (NIR) imaging
Number of subjects: 9
Study 23620431 — intervention group
Group type: COMPARATOR
Intervention: Scanning laser ophthalmoscope imaging
Number of subjects: 9
Study 22070641 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Exercise (IE: 5 × 2:2 min at 85% and 40% maximal oxygen uptake)
Number of subjects: 13
Study 22070641 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady State Exercise (SS: 21 min at 60% maximal oxygen uptake)
Number of subjects: 13
Study 22070641 — intervention group
Group type: COMPARATOR
Intervention: Control Session
Number of subjects: 13
Study 19539305 — intervention group
Group type: EXPERIMENTAL
Intervention: Four short sentences
Number of subjects: 3
Study 19539305 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight short sentences
Number of subjects: 3
Study 19539305 — intervention group
Group type: EXPERIMENTAL
Intervention: Four long sentences
Number of subjects: 3
Study 19539305 — intervention group
Group type: EXPERIMENTAL
Intervention: Four random word lists
Number of subjects: 3
Study 16802542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 0
Study 16802542 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 12588571 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based quadriceps resistance exercise
Number of subjects: 243
Study 12588571 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (calciferol, 300,000 IU)
Number of subjects: 243
Study 12588571 — intervention group
Group type: COMPARATOR
Intervention: Home-based quadriceps resistance exercise and Vitamin D
Number of subjects: 243
Study 10886041 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 36
Study 10886041 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 36
Study 10886041 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 36
Study 9372716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser trabeculoplasty
Number of subjects: 11
Study 9372716 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty
Number of subjects: 11
Study 1535020 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate depot 3.75 mg injected every 24 days
Number of subjects: 67
Study 1535020 — intervention group
Group type: COMPARATOR
Intervention: Danazol 600-800 mg daily
Number of subjects: 67
Study 3554485 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedilhydrochloride (Loftyl)
Number of subjects: 10
Study 3554485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31743424 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal individualized treatment regime (ITR) using data from a 2 × 2 crossover study
Number of subjects: 0
Study 29125051 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic learning combined with experiential learning (experiential learning group)
Number of subjects: 30
Study 29125051 — intervention group
Group type: COMPARATOR
Intervention: Didactic learning alone (no experiential learning group)
Number of subjects: 30
Study 27343714 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 82
Study 27343714 — intervention group
Group type: COMPARATOR
Intervention: Placebo feedback (PF)
Number of subjects: 82
Study 24881805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar continuous theta burst stimulation (cTBS) for two weeks
Number of subjects: 0
Study 24881805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar continuous theta burst stimulation (cTBS)
Number of subjects: 0
Study 24881805 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 22278950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourette syndrome patients
Number of subjects: 11
Study 22278950 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 11
Study 20609226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential medium (group A)
Number of subjects: 147
Study 20609226 — intervention group
Group type: COMPARATOR
Intervention: Single medium (group B)
Number of subjects: 147
Study 18711172 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4 mg intravenously every 3 months for 1 year
Number of subjects: 101
Study 18711172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 14962261 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment with etoposide 80 mg/m² and thioguanine 100 mg/m² twice daily on 5 days and idarubicin 15 mg/m² on 3 days (ETI)
Number of subjects: 92
Study 14962261 — intervention group
Group type: COMPARATOR
Intervention: Intravenous combination of cytarabine 100 mg/m² twice daily on 5 days, idarubicin 12 mg/m² x 1, and thioguanine (TAI)
Number of subjects: 92
Study 11422429 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin (12 U) injected into the carpal tunnel weekly for 7 weeks
Number of subjects: 43
Study 11422429 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected into the carpal tunnel weekly for 7 weeks
Number of subjects: 43
Study 9422907 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia administered before tooth removal
Number of subjects: 78
Study 9422907 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia administered after tooth removal
Number of subjects: 78
Study 8387410 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of tetravalent reassortant rhesus rotavirus vaccine (4 x 10(4) PFU)
Number of subjects: 95
Study 8387410 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of tetravalent reassortant rhesus rotavirus vaccine (4 x 10(5) PFU)
Number of subjects: 95
Study 8387410 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of tetravalent reassortant rhesus rotavirus vaccine
Number of subjects: 95
Study 8387410 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of tetravalent reassortant rhesus rotavirus vaccine
Number of subjects: 95
Study 8387410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle feeding
Number of subjects: 95
Study 8387410 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined serum and salivary responses
Number of subjects: 95
Study 8387410 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum responses alone
Number of subjects: 95
Study 8387410 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary responses in newborn breastfed infants
Number of subjects: 95
Study 2441633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara‐AMP with human leukocyte interferon
Number of subjects: 64
Study 2441633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara‐AMP with placebo
Number of subjects: 64
Study 2441633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2441633 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 64
Study 2441633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara‐AMP
Number of subjects: 64
Study 29933718 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg per day for 12 weeks)
Number of subjects: 68
Study 29933718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg cellulose acetate per day for 12 weeks)
Number of subjects: 68
Study 27733521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amylose maize resistant starch type 2 (HAM-RS2) bagel (25 g/d)
Number of subjects: 24
Study 27733521 — intervention group
Group type: COMPARATOR
Intervention: Control wheat bagel
Number of subjects: 24
Study 24113808 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive counsel for typical medical decisions
Number of subjects: 2562
Study 24113808 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive counsel for morally controversial medical decisions
Number of subjects: 2562
Study 24113808 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive counsel after reading a vignette about palliative sedation
Number of subjects: 2562
Study 22115804 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PTBIED (group A)
Number of subjects: 43
Study 22115804 — intervention group
Group type: COMPARATOR
Intervention: Conventional PTBIED (group B)
Number of subjects: 43
Study 20804058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anesthesia (induced by speeding up propofol injection and maintaining general anesthesia at 4.4-9 mg/kg x hr)
Number of subjects: 25
Study 18414111 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 32
Study 18414111 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 32
Study 18414111 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide and Timolol
Number of subjects: 32
Study 16648211 — intervention group
Group type: EXPERIMENTAL
Intervention: Light orthodontic force of 25 cN
Number of subjects: 8
Study 16648211 — intervention group
Group type: COMPARATOR
Intervention: Heavy orthodontic force of 225 cN
Number of subjects: 8
Study 14723093 — intervention group
Group type: EXPERIMENTAL
Intervention: Evra patch, worn for 7 days
Number of subjects: 0
Study 14723093 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptives (COCs), taken daily
Number of subjects: 0
Study 11010941 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Fe/d as ferrous sulfate for 12 weeks
Number of subjects: 57
Study 11010941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8772471 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hydrocortisone (oral administration)
Number of subjects: 16
Study 8772471 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms of corticotropin-releasing hormone (intravenous administration)
Number of subjects: 16
Study 8772471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study 1478809 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage with suction (Group B1, 52 patients)
Number of subjects: 173
Study 1478809 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage with gravity (Group B2, 35 patients)
Number of subjects: 173
Study 1478809 — intervention group
Group type: COMPARATOR
Intervention: No drainage (Group A, 86 patients)
Number of subjects: 173
Study 1478809 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage (Group B, 87 patients)
Number of subjects: 173
Study 6229735 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg/day)
Number of subjects: 383
Study 6229735 — intervention group
Group type: COMPARATOR
Intervention: Ergot derivative
Number of subjects: 383
Study 31631184 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by surgeons
Number of subjects: 46
Study 31631184 — intervention group
Group type: COMPARATOR
Intervention: Training by peer monitors
Number of subjects: 46
Study 29992869 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (home visiting program 'Pro Kind')
Number of subjects: 39
Study 29992869 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and current parental stress, enriched family learning environment, children's language competencies
Number of subjects: 39
Study 27402235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose edoxaban
Number of subjects: 2349
Study 27402235 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban
Number of subjects: 2349
Study 27402235 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2349
Study 27402235 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis use
Number of subjects: 2349
Study 25011720 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-TAVR
Number of subjects: 1040
Study 25011720 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-TAVR
Number of subjects: 1040
Study 25011720 — intervention group
Group type: EXPERIMENTAL
Intervention: AVR
Number of subjects: 1040
Study 22814850 — intervention group
Group type: EXPERIMENTAL
Intervention: LiRIS 200 mg
Number of subjects: 16
Study 22814850 — intervention group
Group type: EXPERIMENTAL
Intervention: LiRIS 650 mg
Number of subjects: 16
Study 22814850 — intervention group
Group type: EXPERIMENTAL
Intervention: LiRIS 200 mg and 650 mg
Number of subjects: 16
Study 20632059 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.4% glyceryl trinitrate (GTN) treatment for 40 days
Number of subjects: 188
Study 20632059 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.4% glyceryl trinitrate (GTN) treatment for 80 days
Number of subjects: 188
Study 20632059 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.4% glyceryl trinitrate (GTN) treatment (both groups)
Number of subjects: 188
Study 17846259 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 202
Study 17846259 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 202
Study 17846259 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (sertraline, 50-200 mg daily)
Number of subjects: 202